These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation. Foss FM Semin Hematol; 2006 Apr; 43(2 Suppl 2):S35-43. PubMed ID: 16549113 [TBL] [Abstract][Full Text] [Related]
3. Reduced intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease. Turner BE; Kambouris ME; Sinfield L; Lange J; Burns AM; Lourie R; Atkinson K; Hart DN; Munster DJ; Rice AM Transplantation; 2008 Oct; 86(7):968-76. PubMed ID: 18852664 [TBL] [Abstract][Full Text] [Related]
4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
5. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation. Strober S Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036 [TBL] [Abstract][Full Text] [Related]
6. Nonmyeloablative and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation: a clinical review. Pollack SM; O'Connor TP; Hashash J; Tabbara IA Am J Clin Oncol; 2009 Dec; 32(6):618-28. PubMed ID: 19593085 [TBL] [Abstract][Full Text] [Related]
7. Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial. Markova M; Barker JN; Miller JS; Arora M; Wagner JE; Burns LJ; MacMillan ML; Douek D; DeFor T; Tan Y; Repka T; Blazar BR; Weisdorf DJ Bone Marrow Transplant; 2007 Feb; 39(4):193-9. PubMed ID: 17220905 [TBL] [Abstract][Full Text] [Related]
8. Hematopoietic stem cell therapy for malignant diseases. Shapira MY; Hai AA; Tsirigotis P; Resnick IB; Or R; Slavin S Ann Med; 2007; 39(6):465-73. PubMed ID: 17852026 [TBL] [Abstract][Full Text] [Related]
9. Infectious complications in chronic graft-versus-host disease: a retrospective study of 145 recipients of allogeneic hematopoietic stem cell transplantation with reduced- and conventional-intensity conditioning regimens. Yamasaki S; Heike Y; Mori S; Fukuda T; Maruyama D; Kato R; Usui E; Koido K; Kim S; Tanosaki R; Tobinai K; Teshima T; Takaue Y Transpl Infect Dis; 2008 Jul; 10(4):252-9. PubMed ID: 18194371 [TBL] [Abstract][Full Text] [Related]
10. A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors. Conrad R; Remberger M; Cederlund K; Ringdén O; Barkholt L Haematologica; 2008 Feb; 93(2):265-72. PubMed ID: 18245651 [TBL] [Abstract][Full Text] [Related]
11. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and acute myelogenous leukemia. Valcárcel D; Martino R Curr Opin Oncol; 2007 Nov; 19(6):660-6. PubMed ID: 17906468 [TBL] [Abstract][Full Text] [Related]
12. Is reduced-intensity conditioning the standard of care in the transplant setting? Giralt SA Clin Adv Hematol Oncol; 2008 May; 6(5):337-9. PubMed ID: 18516022 [No Abstract] [Full Text] [Related]
13. Reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. Alousi A; de Lima M Clin Adv Hematol Oncol; 2007 Jul; 5(7):560-70. PubMed ID: 17679930 [TBL] [Abstract][Full Text] [Related]